Bausch Health Companies Inc.
BHC- Exchange
- NYSE
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0000885590
In the last 90 days, Bausch Health Companies Inc. insiders filed 0 open-market purchases and 1 sale; 219 institutions reported holding it in 13F filings for Q2 2026, worth $1.18B in total; no superinvestor holds it.
- Currency
- USD
- Source
- SEC XBRL data (10-K, 10-Q, 20-F, 40-F)
- Updated
- Oct 30, 2026, 1:15 AM ET
Revenue flow, FY2025
Where the revenue went in FY2025, from the income statement below. Green is profit; orange is costs, expenses and taxes. Percentages are shares of revenue; hover over a band or a bar for the exact amount.
Income statement
Each column is one fiscal year, newest first.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Jan 13, 2026 | Feb 19, 2025 | Feb 22, 2024 | Feb 23, 2023 | Feb 23, 2022 |
| Revenue | $10.3B | $9.63B | $8.76B | $8.12B | $8.43B |
| Research and development | $629.0M | $616.0M | $604.0M | $529.0M | $465.0M |
| Selling, general and administrative | $3.44B | $3.30B | $2.92B | $2.63B | $2.62B |
| Operating income | $1.81B | $1.55B | $963.0M | $454.0M | $450.0M |
| Interest expense | $1.60B | $1.39B | $1.33B | $1.46B | $1.43B |
| Income tax | $247.0M | $239.0M | $221.0M | $83.0M | -$87.0M |
| Net income | $157.0M | -$46.0M | -$592.0M | -$225.0M | -$948.0M |
| EPS, basic | $0.42 | $-0.13 | $-1.62 | $-0.62 | $-2.64 |
| EPS, diluted | $0.42 | $-0.13 | $-1.62 | $-0.62 | $-2.64 |
| Weighted shares, basic | 370.9M | 368.0M | 364.9M | 362.0M | 358.9M |
| Weighted shares, diluted | 375.0M | 368.0M | 364.9M | 362.0M | 358.9M |
| Margins and growth | |||||
| Operating margin | 17.7% | 16.1% | 11.0% | 5.6% | 5.3% |
| Net margin | 1.5% | -0.5% | -6.8% | -2.8% | -11.2% |
| Revenue growth, year over year | +6.7% | +9.9% | +7.8% | −3.7% | +5.1% |
Balance sheet
Each column is one fiscal year, newest first.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Jan 13, 2026 | Feb 19, 2025 | Feb 22, 2024 | Feb 23, 2023 | Feb 23, 2022 |
| Cash and equivalents | $1.31B | $1.18B | $947.0M | $564.0M | $582.0M |
| Accounts receivable | $2.35B | $2.14B | $2.00B | $1.79B | $1.77B |
| Inventory | $1.63B | $1.59B | $1.54B | $1.09B | $993.0M |
| Total current assets | $6.16B | $5.77B | $5.60B | $4.25B | $5.61B |
| Property, plant and equipment | $2.07B | $1.78B | $1.71B | $1.60B | $1.60B |
| Goodwill | $11.3B | $11.1B | $11.2B | $11.5B | $12.5B |
| Intangible assets | $4.64B | $5.55B | $6.46B | $5.80B | $6.95B |
| Total assets | $26.4B | $26.5B | $27.4B | $25.7B | $29.2B |
| Accounts payable | $600.0M | $656.0M | $719.0M | $521.0M | $407.0M |
| Short-term debt | $225.0M | $2.67B | $450.0M | $432.0M | $0 |
| Total current liabilities | $4.18B | $6.75B | $4.30B | $3.94B | $5.20B |
| Long-term debt | $20.6B | $18.9B | $21.9B | $20.3B | $22.7B |
| Total liabilities | $26.0B | $26.8B | $27.4B | $25.4B | $29.2B |
| Shareholders' equity | $377.0M | -$322.0M | -$82.0M | $260.0M | -$34.0M |
Cash flow statement
Each column is one fiscal year, newest first. Free cash flow is operating cash flow minus capital expenditures.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Jan 13, 2026 | Feb 19, 2025 | Feb 22, 2024 | Feb 23, 2023 | Feb 23, 2022 |
| Operating cash flow | $1.40B | $1.60B | $1.03B | -$728.0M | $1.43B |
| Capital expenditures | $397.0M | $337.0M | $215.0M | $218.0M | $269.0M |
| Free cash flow | $1.00B | $1.26B | $817.0M | -$946.0M | $1.16B |
| Depreciation and amortization | $1.21B | $1.27B | $1.26B | $1.39B | $1.55B |
| Stock-based compensation | $216.0M | $150.0M | $132.0M | $126.0M | $128.0M |
| Investing cash flow | -$595.0M | -$454.0M | -$2.15B | -$303.0M | $409.0M |
| Financing cash flow | -$742.0M | -$868.0M | $1.48B | -$474.0M | -$1.51B |
| Net change in cash | $124.0M | $239.0M | $371.0M | -$1.53B | $303.0M |
| Ratio | |||||
| Stock-based compensation, % of revenue | 2.1% | 1.6% | 1.5% | 1.6% | 1.5% |
Shares outstanding
Common shares outstanding as stated on the cover of each 10-K and 10-Q. The date is the cover date, not the period end; a rising count means dilution.
| Cover date | Shares outstanding | Change in a year | Filing |
|---|---|---|---|
| Oct 23, 2026 | 374.3M | +1.0% | SEC |
| Jul 24, 2026 | 374.0M | +1.1% | SEC |
| Apr 24, 2026 | 373.5M | +1.1% | SEC |
| Feb 13, 2026 | 370.6M | +0.7% | SEC |
| Oct 24, 2025 | 370.5M | +0.7% | SEC |
| Jul 25, 2025 | 369.8M | +0.7% | SEC |
| Apr 25, 2025 | 369.6M | +0.8% | SEC |
| Feb 14, 2025 | 367.9M | +0.7% | SEC |
Notes and known gaps
How these numbers are put together, and what they can't tell you.
- Numbers come from the XBRL data in each period's original 10-K, 10-Q, 20-F or 40-F, or its amendment. They are shown as filed: later filings don't restate earlier periods here.
- Reported is the filing date of the first 8-K with Item 2.02 (results of operations) after the period ended, no later than the 10-Q or 10-K and within 120 days. Companies that release results only in the 10-Q, and foreign companies, which use Form 6-K, have none.
Known gaps
- Foreign companies that file Form 20-F or 40-F have annual statements only: their quarterly results are furnished on Form 6-K, which has no XBRL data.
- EPS and share counts are as reported at the time, not adjusted for later stock splits.
- For ADRs, EPS is per ordinary share, not per ADS (one TSMC ADS is five ordinary shares).
- For banks, revenue may be interest income only, depending on how the bank tags its filings; cost of revenue and gross profit are usually blank.
- Companies with several share classes, such as Berkshire Hathaway, may have no EPS and no cover share count.
- Depreciation and amortization is missing for some companies that report it under their own XBRL tags.